Manufacturer Ensures Ongoing Availability of Fampyra for MS Patients in Germany

The pharmaceutical company responsible for Fampyra, a treatment designed to improve walking ability in adults with multiple sclerosis (MS), has confirmed the continued availability of the medication in Germany. Fampyra contains the active ingredient fampridine in an extended-release formulation, which has been approved since 2011 for adults with MS who experience difficulties with mobility.

Fampridine functions as a selective potassium channel blocker, targeting nerve fibers that have lost their myelin sheath but remain otherwise intact. This mechanism can enhance both walking speed and mobility in suitable patients. The drug's efficacy is dependent on the presence of demyelinated yet structurally intact axons, allowing for improved nerve signal transmission.

Recently, the German market saw the temporary introduction of generic versions of fampridine while legal disputes regarding patent rights were ongoing. However, following a final ruling by the Federal Court of Justice upholding the validity of the patents for Fampyra, these generic alternatives are no longer available. The original manufacturer, Merz Therapeutics, has emphasized that Fampyra 10 mg extended-release tablets remain accessible to patients across Germany, ensuring uninterrupted treatment options.

Merz Therapeutics has also stated that the supply of Fampyra is secure for both existing and new patients, with patent protections in place until the end of July 2026. The company has stressed its commitment to maintaining a stable and reliable supply chain to meet the needs of individuals with multiple sclerosis who rely on this therapy to manage their mobility challenges.

Multiple sclerosis is a chronic neurological condition in which the immune system attacks the protective covering of nerve fibers, resulting in a range of symptoms, including impaired movement. Treatments like Fampyra provide essential support for those affected by MS, particularly in managing everyday activities that depend on walking and mobility.

The reassurance provided by Merz Therapeutics comes at a critical time for MS patients who may have faced uncertainty due to the brief presence of generic alternatives and the ongoing legal proceedings. With the legal situation now clarified, healthcare professionals and patients can continue to access Fampyra as part of individualized MS care plans.

Healthcare providers are encouraged to remain informed about the current status of MS treatments and to advise patients accordingly. The sustained availability of Fampyra under patent protection ensures that individuals with MS in Germany have continued access to a medication that can significantly impact their quality of life.